Protein Expertise at Gallus
Fusion Proteins (125—300 kDaltons)
- 3-part fusion protein, produced material for Phase 1—3 clinical trials; Co-published downstream process with client, Enobia Pharma (Biopharm International, March 2008)
- Developed new upstream & downstream processes for three other fusion proteins
IgM antibodies (1000 kDaltons)
- Increased upstream titer 2—5X
- Worked with PER.C6® and Hybridomas
- Co-published data on first PER.C6 IgM process with client, Patrys Ltd. (BioProcess International, December 2011)
Heavily glycosylated molecules, including Interleukin with 30% carbohydrate
- Enhanced production and recovery of fully sialated protein
- Produced multiple lots over six-year period
Enzymes
- Modified client downstream process to protect enzyme from autolysis
- Developed new process to remove undesirable variant
IgG Variants
- 3 aglycosylated IgGs, solubility issues addressed
- 2 deletion mutants with expression & purification issues
IgG Antibodies
- Over 40 unique IgGs produced from CHO, NSO & Hybridoma cell lines
- Human, humanized, chimeric and murine forms
Structure Proteins (900 KDa)
- 900 KDa structure protein with heavy hydroxylation.
Full protein Characterization capability
Sequence coverage by LC-MS/MS, MW by ESI-TOF, AAA, Extinction Coefficient Determination, Glycan profiling, Sialic Acid content analysis, CE analysis, Subvisible particle measurement, SEC-MALS, Cell-based potency assay